Novel methoxybenzamibe compounds for use in mch receptor related disorders

摘要

Novel compounds of Formula (I) which modulate MCH activity are disclosed, in which A is a linker; Ar₁ is an aryl or heteroaryl group; R1 is a lower alkoxy group; R2 is an R1 group or hydrogen, an OH or an NH₂ group, Q together with the carbonyl forms an amide group, which is further substituted with an amine group; R5 is selected from hydrogen, halogen atoms, alkoxy groups, hydroxy, alkylamino groups, dialkylamino groups, hydroxylalkyl groups, carboxamido groups, acylamido groups, acyl groups, -CHO, nitrile, alkyl, alkenyl or alkynyl groups, -SCH₃, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as -CH₂CF₃, -CF₂CF₃, -CF₃, -OCF₃, -SCF₃; -SO₂NH₂, -SO₂NHAlk, -SO₂NAlk₂, -SO₂Alk; X is H, F, Cl, Br, I, -SCH₃, -CF₃, -OCF₃, -SCF₃, OCH₃, or lower alkyl or alkenyl group; R8 is halogen atoms, alkyl, alkenyl or alkynyl groups, cycloalkyl groups, aryl groups, heteroaryl groups, heterocyclyl groups, alkylcycloalkyl groups, alkylaryl groups, alkylheterocyclyl groups, alkylheteroaryl groups, arylalkoxy groups, aryloxy groups, alkoxy groups, dialkylamino groups, -CONHAlk, -CONHAr, -CONAlk₂, -NHCO-Alk, -NHCO-Ar, -CO-Alk, -CO-Ar, -SCH₃, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups; or R8 is R6-Ar₂-B-, in which B is a single bond or a connecting moiety; Ar₂ is an Ar₁ group; R6 is an R5 group; and which are useful in the treatment or prevention of e.g. obesity, depression, diabetes, bulimia etc.